Skip to content.

Sundial Growers finalizes license agreement and share purchase transaction with Pathway Rx.

Date Closed

July 31, 2019

Lead Office


On July 5, 2019, Sundial Growers and Pathway Rx filed a share purchase agreement in which Sundial acquired 50% of the issued and outstanding shares of Pathway in consideration for an aggregate 296,800 common shares. This transaction is a central part of Sundial's strategy to enter the Canadian medical cannabis business and provide medical cannabis products targeted for use with specific medical conditions.

Sundial Growers is a licensed cannabis producer based in Alberta which provides recreational and medical cannabis products.

McCarthy Tétrault advised Sundial with a team led by Greg Turnbull that included Nathan Robb, Curtis Merry, Simran Choongh (Business) and Vincent Yip (Intellectual Property).